Dyne Therapeutics, INC

Dyne Therapeutics announced its second quarter 2026 financial results, highlighting significant progress in its clinical pipeline for rare neuromuscular diseases and a strong cash position extending runway into Q2 2028.

Dyne Therapeutics announced the pricing of an upsized public offering of common stock, raising substantial capital to fund its operations and development programs.

Dyne Therapeutics announced its biologics license application for zeleciment rostudirsen (DYNE-251) for Duchenne muscular dystrophy has been accepted for FDA Priority Review, with a target action date of January 21, 2027.

Dyne Therapeutics amended its loan agreement with Hercules Capital, increasing the total debt facility to $400 million and borrowing an initial $50 million tranche.

Dyne Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including director elections, executive compensation approval, and amendments to its charter.

Dyne Therapeutics announced full enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for zeleciment basivarsen in myotonic dystrophy type 1 patients.

Dyne Therapeutics reported a wider net loss for Q1 2026, driven by increased research and development expenses, particularly for its z-rostudirsen program, while general and administrative costs also rose.

Dyne Therapeutics reports positive clinical data for its lead programs, z-basivarsen and z-rostudirsen, while securing significant financing to extend its cash runway into Q3 2027.

Dyne Therapeutics announced positive long-term efficacy and safety data for its lead programs, DYNE-101 for DM1 and DYNE-251 for DMD, alongside securing significant financing that extends its cash runway into the third quarter of 2027.

Dyne Therapeutics reports the separation of an executive, Q1 2025 financial results, and provides updates on its ongoing clinical trials for DYNE-101 and DYNE-251.

Dyne Therapeutics' Q3 2024 filing highlights a robust cash position of $723.7 million and positive clinical trial data for its lead programs.

Dyne Therapeutics' Q2 2024 filing reveals a robust cash position and encouraging clinical trial results for its lead programs.

Dyne Therapeutics reports significant clinical progress for DMD and DM1 programs, secures substantial financing, and expands its pipeline for genetically driven neuromuscular diseases.

Dyne Therapeutics, a clinical-stage company, is advancing its pipeline of neuromuscular disease therapeutics, but continues to incur significant losses and requires substantial additional funding.

Dyne Therapeutics' 10-K filing details the company's financial status and progress in developing treatments for muscle diseases, including positive initial clinical data for its DM1 and DMD programs.

Dyne Therapeutics Director Jason P. Rhodes reported the sale of common stock totaling over 600,000 shares across multiple transactions on July 6th and 7th, 2026, executed under a Rule 10b5-1 trading plan.

Dyne Therapeutics Director Jason P. Rhodes reported the sale of common stock valued at approximately $21.28 per share on June 26, 2026, and $21.14 per share on June 29, 2026, pursuant to a Rule 10b5-1 trading plan.

Dyne Therapeutics' Chief Financial Officer, Erick Lucera, sold 2,362 shares of common stock on June 25, 2026, to cover tax obligations related to vested restricted stock units.

Dyne Therapeutics Director Jason P. Rhodes reported the sale of common stock totaling over 100,000 shares across multiple transactions between June 23-25, 2026, executed under a Rule 10b5-1 trading plan.

Dyne Therapeutics Director Dirk Kersten reported transactions involving the sale of company stock, executed under a Rule 10b5-1 trading plan.

Dyne Therapeutics Chief Medical Officer Douglas Kerr sold company stock to cover tax obligations related to vested restricted stock units.

Dyne Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

Dyne Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 30, 2025, featuring director elections, executive compensation votes, and auditor ratification.

Dyne Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.

Dyne Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 22, 2024, to vote on director elections and the ratification of its accounting firm.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.0% of Dyne Therapeutics, Inc. common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 13,647,376 shares of Dyne Therapeutics Inc. common stock, representing 8.3% of the class.

T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 18.7% in Dyne Therapeutics Inc., as of March 31, 2026.

FMR LLC has reported beneficial ownership of 5.4% of Dyne Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Dyne Therapeutics Inc., reporting zero beneficial ownership following an internal realignment.

T. Rowe Price Investment Management, Inc. reported an increased beneficial ownership of 16.2% in Dyne Therapeutics Inc. common stock.